EFFICIENCY OF ADJUVANT XELOX CHEMOTHERAPY FOR PATIENTS WITH RESECTABLE GASTRIC IN RUSSIA (SINGLE INSTITUTION RETROSPECTIVE STUDY)

2019 ◽  
Vol 65 (2) ◽  
pp. 256-262
Author(s):  
Ivan Stilidi ◽  
Sergey Nered ◽  
Aleksey Kalinin ◽  
Olesya Rossomakhina ◽  
Anton Barchuk
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Radical Surgery ◽  
Univariate Analysis ◽  
European Population ◽  
Single Institution ◽  
Regional Lymph Nodes ◽  
Lymph Nodes Metastasis ◽  
Retrospective Assessment ◽  
Resectable Gastric Cancer

Introduction. The effectiveness of the Asian regimen of adjuvant chemotherapy in patients with gastric cancer in the European population remains unclear. The aim of our study was a retrospective assessment of adjuvant chemotherapy (XELOX regimen) after radical surgery (R0) on overall survival. Methods. Database of pts with resectable gastric cancer with stage >pT3 and/or pN+ and M0, who were operated (R0) at single oncological institution during 2007-2017 was reviewed. In univariate and multivariate analyzes were included demographic characteristics, type of tumor according to Lauren, stage, type of treatment and others. Results. 396 pts were identified and 286 were available for analysis.106 (37%) pts received at least one cycle of adjuvant chemotherapy. In univariate analysis, 5OS rate was 64% [95% Cl, 52-80] и 56% [95% Cl, 48-64; p=0,21] in patients received adjuvant chemotherapy and only surgical treatment. After stratifying patients depending on the regional lymph nodes metastasis, 5OS rate in pts with pN1-3 was 69% [95% CI, 57-85] vs 47% [95% CI, 39-58; p = 0,01], respectively...

Prognostic factors in resectable gastric cancer: Results of EORTC study no. 40813 on FAM adjuvant chemotherapy

1995 ◽  
Vol 2 (6) ◽  
pp. 495-501 ◽  
Author(s):  
Mario Lise ◽  
Donato Nitti ◽  
Alberto Marchet ◽  
Tarek Sahmoud ◽  
Nicole Duez ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factors ◽  
Adjuvant Chemotherapy ◽  
Resectable Gastric Cancer

Is There a Benefit for Added Radiation to Adjuvant Chemotherapy after D2 Gastrectomy for Resectable Gastric Cancer?

2019 ◽  
Vol 229 (4) ◽  
pp. S268
Author(s):  
Michael J. Jalfon ◽  
Miriam Tsao ◽  
Benjamin W. Deschner ◽  
Paxton V. Dickson ◽  
Jeremiah L. Deneve ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
D2 Gastrectomy ◽  
Resectable Gastric Cancer

scholarly journals Optimal Duration of Fluorouracil-Based Adjuvant Chemotherapy for Patients with Resectable Gastric Cancer

PLoS ONE ◽  
2013 ◽  
Vol 8 (12) ◽  
pp. e83196 ◽  
Author(s):  
Jing-lei Qu ◽  
Xin Li ◽  
Xiu-juan Qu ◽  
Zhi-tu Zhu ◽  
Li-zhong Zhou ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Optimal Duration ◽  
Resectable Gastric Cancer

Role of systemic immune-inflammatory index, tumor infiltrating neutrophils and PD-1+ T cells to predict the postoperative recurrence after S-1 adjuvant chemotherapy for gastric cancer: A retrospective study.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 74-74
Author(s):  
Hiroaki Tanaka ◽  
Tatsuro Tamura ◽  
Soichiro Hiramatsu ◽  
Kazuya Muguruma ◽  
Yuichiro Miki ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
T Cells ◽  
Adjuvant Chemotherapy ◽  
Prognostic Score ◽  
Univariate Analysis ◽  
Glasgow Prognostic Score ◽  
Predictive Marker ◽  
Stage Ii ◽  
University Hospital ◽  
Neutrophil Lymphocyte Ratio

74 Background: The adjuvant chemotherapy with S-1 is the standard treatment for Stage II/III gastric cancer in Japan. Immunological status of host is critical for treatment outcome. Several investigators showed that systemic immune-inflammaotry indexes including neutrophil lymphocyte ratio (NLR) and modified Glasgow Prognostic Score (mGPS) well reflected the tumor progression. Methods: We analyzed clinical data obtained from 170 patients with pathological stage II/III gastric cancer who underwent surgery followed by S-1 adjuvant chemotherapy at Osaka City University Hospital between 2006 and 2015. Tumor infiltrating cells were detected by immunohistochemistry. Results: We found recurrent diseases in 70 (41%) patients including 15 in stage II and 55 in stage III. In univariate analysis using Cox proportion model, 2 grade of mGPS, the increase value of post-operative CEA, CA19-9, number of lymphocytes and NLR were associated with recurrence. Post-operative elevation of CEA and NLR were identified as independent risk factors for recurrence in multivariate analysis. Increase value of pre-operative NLR and CEA was significantly associated with early recurrent within one year after surgery. Tumor infiltrating neutrophils and PD-1+ T cells had correlated with the increase of pre-operative NLR and CEA value, respectively. Patients with low PD-1+T cells and low neutrophils had better prognosis than those with high infiltration. Conclusions: Post-surgical elevation of CEA and NLR value were useful as a predictive marker for recurrence in patients treated with S-1 adjuvant chemotherapy after surgery for gastric cancer. Early recurrence had correlated with tumor infiltrating neutrophils and PD-1+T cells. Our results suggested that systemic and local immune suppression should be an important element to exacerbate prognosis after chemotherapy for resectable gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document